SynthesisBMC cancer2024
Survival prediction of glioblastoma patients using machine learning and deep learning: a systematic review.
Synthesis in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Research on machine learning-based clinical prediction models: a bibliometric analysis.Frontiers in oncology · 2026Pooled it
- Advances in Nanomedicine for Brain Tumors: Overcoming Biological Barriers, Targeting Strategies, and Future Directions.Current neurology and neuroscience reports · 2026Review
- Survival Outcomes and Machine Learning-Based Prediction of 12-Month Mortality in Glioblastoma Before and During the COVID-19 Pandemic: A SEER Population-Based Study.Medicina (Kaunas, Lithuania) · 2026Article
- Article
- Potential therapeutic targeting of BKMolecular oncology · 2026Review
- Artificial Intelligence-Based MRI Segmentation in Glioblastoma and Single Brain Metastasis: An Exploratory Study of Diagnostic and Prognostic Value.Life (Basel, Switzerland) · 2026Article
- Machine Learning-Based Classification of Gliomas and Tumor Grades with SHAP-Guided Feature Interpretation.Genes · 2026Article
- Machine-Learning-Based Survival Prediction in Glioblastoma Using Graph-Theoretical Analysis of Structural Network Alterations.Cancers · 2026Article
- From imaging to omics: deep learning is bridging MRI and liquid biopsy in bone tumor diagnosis.Journal of bone oncology · 2026Review
- Integrating Blood-Based Immune-Inflammation Biomarkers into Artificial Intelligence-Driven Prognostic Models in Oncology.International journal of molecular sciences · 2026Review
- Characterizing malignant prognostic signatures in primary glioma based on single-cell and bulk transcriptome sequencing.PloS one · 2026Article
- Engineering spherical nucleic acids for precision cancer therapy: design strategies and medical applications.Theranostics · 2026Review
- Engineering a modular FAP-targeting ferritin-based drug nanocarrier for enhanced glioblastoma theranostics.Theranostics · 2026Article
- AI-driven network pharmacology and multi-omics validation identify KCNH2 as a prognostic biomarker and candidate therapeutic vulnerability of Acorus tatarinowii in glioblastoma.Frontiers in pharmacology · 2026Article
- Predicting the Regulatory Dynamics of AML Disease Progression from Longitudinal Multi-Modal Clinical Data.Journal of medical systems · 2025Article
- GlioSurv: interpretable transformer for multimodal, individualized survival prediction in diffuse glioma.NPJ digital medicine · 2025Article
- Artificial intelligence in neuro-oncology: methodological bases, practical applications and ethical and regulatory issues.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- Automated feature learning and survival prognostication in grade 4 glioma using supervised machine learning models.Journal of neuro-oncology · 2025Article
- Artificial Intelligence-Driven Multi-Omics Approaches in Glioblastoma.International journal of molecular sciences · 2025Review
- Artificial Intelligence in the Diagnosis and Treatment of Brain Gliomas.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma Multiforme (GBM), classified as a grade IV glioma by the World Health Organization (WHO), is a prevalent and notably aggressive form of brain tumor derived from glial cells. It stands as one of the most severe forms of primary brain cancer in humans. The median survival time of GBM patients is only 12-15 months, making it the most lethal type of brain tumor. Every year, about 200,000 people worldwide succumb to this disease. GBM is also highly heterogeneous, meaning that its characteristics and behavior vary widely among different patients. This leads to different outcomes and survival times for each individual. Predicting the survival of GBM patients accurately can have multiple benefits. It can enable optimal and personalized treatment planning based on the patient's condition and prognosis. It can also support the patients and their families to cope with the possible outcomes and make informed decisions about their care and quality of life. Furthermore, it can assist the researchers and scientists to discover the most relevant biomarkers, features, and mechanisms of the disease and to design more effective and personalized therapies. Artificial intelligence methods, such as machine learning and deep learning, have been widely applied to survival prediction in various fields, such as breast cancer, lung cancer, gastric cancer, cervical cancer, liver cancer, prostate cancer, and covid 19. This systematic review summarizes the current state-of-the-art methods for predicting glioblastoma survival using different types of input data, such as clinical features, molecular markers, imaging features, radiomics features, omics data or a combination of them. Following PRISMA guidelines, we searched databases from 2015 to 2024, reviewing 107 articles meeting our criteria. We analyzed the data sources, methods, performance metrics and outcomes of the studies. We found that random forest was the most popular method, and a combination of radiomics and clinical data was the most common input data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.